ERBB2 and breast carcinoma: In the M0 cohort, we found that serum miR-21 median levels were significantly higher in patients with HER2+ than in patients with HER2− breast cancer and HDs and this difference could distinguish patients with HER2+ breast cancer from patients with HER2− breast cancer and HDs.